改良乳腺癌根治术联合表柔比星治疗乳腺癌的疗效及对血清抵抗素、脂联素水平的影响

目的:探究改良乳腺癌根治术联合表柔比星治疗乳腺癌的疗效及对血清抵抗素、脂联素水平的影响.方法:收集2019年1月～2020年1月我院确诊为乳腺癌的60例患者资料,使用随机数字法将患者分为对照组、观察组,每组30例.两组患者均接受改良乳腺癌根治术,对照组患者在此基础上接受阿霉素、环磷酰胺、5-氟尿嘧啶治疗,观察组接受表;...

Effect of Modified Radical Mastectomy Combined with Epirubicin in the Treatment of Breast Cancer and Research Progress on Serum Resistin and Adiponectin Levels

ABSTRACT Objective: To explore the effect of modified radical mastectomy combined with epirubicin in the treatment of breast cancer and its influence on serum resistin and adiponectin levels. Methods: The data of 60 patients with breast cancer diagnosed in our hospital from January 2019 to January 2020 were collected and randomly divided into control group and observation group, 30 cases in each group. Two groups of patientsreceived modified radical mastectomy, the control group received adriamycin, cyclophosphamide, 5-fluorouracil on the basis of the treatment, the observation group received epirubicin and cyclophosphamide combined chemotherapy. The treatment effect, adverse reaction rate, 3-year survival rate, serum resistin and adiponectin levels were compared between the two groups. Results: The clinical efficacy of the observation group (93.33 %) was higher than that of the control group (60.00 %) (P<0.05); the incidence of cardiotoxicity and neutropenia in the observation group (13.33 %, 73.33 %) was lower than that in the control group (30.00 %, 86.67 %) (P<0.05). There was no significant difference in the incidence of nausea, vomiting and liver function damage between the two groups (P>0.05). The 3-year survival rate of the observation group (76.67 %) was higher than that of the control group (63.33 %) (P<0.05). After treatment, the serum resistin and adiponectin levels of the two groups were improved (P<0.05), the serum resistin level in the observation group was lower than that in the control group (P<0.05), and the adiponectin level in the observation group was higher than that in the control group (P<0.05). Conclusion: Modified radical mastectomy combined with epirubicin is effective in the treatment of breast cancer, which can effectively improve the levels of serum resistin and adiponectin.